Zydus Lifesciences Ltd

Zydus Lifesciences Limited confirmed that certificates of equity shares received for dematerialization during the quarter ended September 30, 2026, have been mutilated and cancelled after due verification, according to a regulatory filing with the BSE Limited and the National Stock Exchange of India Limited. The confirmation was based on a certificate received from MUFG Intime India Private Limited, formerly known as Link Intime India Private Limited, which also confirmed that the securities were accepted or rejected by the depositories and listed on the stock exchanges.

Zydus Lifesciences Limited has extended the completion date for its planned 50% investment in Zydus Sunshine Lifesciences (Private) Limited, a joint venture with Sunshine Healthcare Lanka Limited, to December 2026, according to a filing with the BSE Limited and National Stock Exchange of India Limited on October 1, 2026.

Zydus Lifesciences Limited will close its trading window for directors and designated persons and their immediate relatives from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter and half year ending September 30, 2026, as stated in a filing with the BSE Limited and National Stock Exchange of India Limited.

Zydus Lifesciences Ltd gained for a fifth straight session today. The stock is quoting at Rs 1168, up 0.6% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.29% on the day, quoting at 23345.95. The Sensex is at 74614.23, down 0.33%. Zydus Lifesciences Ltd has gained around 5.82% in last one month. Meanwhile, Nifty Pharma index of which Zydus Lifesciences Ltd is a constituent, has gained around 2.24% in last one month and is currently quoting at 27021.15, down 0.34% on the day. The volume in the stock stood at 10.16 lakh shares today, compared to the daily average of 13.26 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 1170.3, up 0.34% on the day. Zydus Lifesciences Ltd is up 11.79% in last one year as compared to a 7.25% slide in NIFTY and a 20.76% slide in the Nifty Pharma index.The PE of the stock is 31.79 based on TTM earnings ending June 26.

Zydus Lifesciences Ltd rose for a third straight session today. The stock is quoting at Rs 1154.5, up 1.71% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.24% on the day, quoting at 23325.6. The Sensex is at 74509.35, up 0.26%. Zydus Lifesciences Ltd has added around 4.53% in last one month. Meanwhile, Nifty Pharma index of which Zydus Lifesciences Ltd is a constituent, has added around 1.14% in last one month and is currently quoting at 26579.25, up 0.13% on the day. The volume in the stock stood at 14.78 lakh shares today, compared to the daily average of 12.44 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 1159, up 1.75% on the day. Zydus Lifesciences Ltd is up 11.3% in last one year as compared to a 7.9% fall in NIFTY and a 17.31% fall in the Nifty Pharma index.The PE of the stock is 31.13 based on TTM earnings ending June 26.

Zydus Lifesciences Ltd announced on September 11, 2026, that CRISIL Ratings Limited reviewed and reaffirmed the credit ratings of its various instruments and facilities, as detailed in letters dated September 10, 2026, including a long term rating of CRISIL AAA/Stable and a short term rating of CRISIL A1+ for Various Bank Facilities amounting to Rs. 4,724 crore; a short term rating of CRISIL A1+ for Commercial Papers (CPs) with an authorized limit of Rs. 200 crore; a rating of CRISIL AAA/Stable for Non-Convertible Debentures (NCDs) with an outstanding limit of Rs. 50 crore; and a rating of CRISIL AAA/Stable for another instrument with an outstanding limit of Rs. 75 crore, noting that there are currently no outstanding Commercial Papers or Non-Convertible Debentures.

Zydus Lifesciences Ltd is up for a third straight session today. The stock is quoting at Rs 1171, up 1.83% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.13% on the day, quoting at 24176.5. The Sensex is at 77361.12, down 0.14%. Zydus Lifesciences Ltd has gained around 6.53% in last one month. Meanwhile, Nifty Pharma index of which Zydus Lifesciences Ltd is a constituent, has gained around 2.95% in last one month and is currently quoting at 26626.3, up 0.52% on the day. The volume in the stock stood at 20.24 lakh shares today, compared to the daily average of 15.31 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 1180.1, up 1.99% on the day. Zydus Lifesciences Ltd is up 19.66% in last one year as compared to a 1.32% slide in NIFTY and a 22.73% slide in the Nifty Pharma index.The PE of the stock is 31.42 based on TTM earnings ending June 26.

Zydus Lifesciences Ltd is down for a fifth straight session today. The stock is quoting at Rs 1106.5, down 0.82% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.46% on the day, quoting at 24043.1. The Sensex is at 76858.54, down 0.49%.Zydus Lifesciences Ltd has lost around 3.7% in last one month.Meanwhile, Nifty Pharma index of which Zydus Lifesciences Ltd is a constituent, has increased around 0.84% in last one month and is currently quoting at 26361.9, down 0.53% on the day. The volume in the stock stood at 9.53 lakh shares today, compared to the daily average of 14.79 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 1108.9, down 0.97% on the day. Zydus Lifesciences Ltd jumped 12.53% in last one year as compared to a 4.02% slide in NIFTY and a 19.36% spurt in the Nifty Pharma index.The PE of the stock is 30.57 based on TTM earnings ending June 26.

Zyudus Lifesciences Limited announced that shareholders at its Thirty First Annual General Meeting on August 11, 2026, approved the re-appointment of Dr. Sharvil P. Patel as Managing Director for a five-year period effective April 1, 2027, to March 31, 2032, and the appointment of Mr. Kulin S. Lalbhai as an Independent Director for a five-year term effective May 19, 2026, to May 18, 2031.

Zydus Lifesciences Ltd share price gained 0.49% to Rs 1120.7 after the company's net profit tanked by 28.99% to Rs 952.4 crore, while revenue from operations slightly gained 4.94% to Rs 7802.0 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.56 lakh crore, gaining 4.63%. It has marginally improved by 0.56% over last one week and climbed by 13.27% in last one month while the market capitalization of Zydus Lifesciences Ltd has inched up 0.20% and 18.32% in the same period respectively. Profit before tax (PBT) of Zydus Lifesciences Ltd stood at Rs 1306.6 crore in Q2 FY26, plunging by 31.97% year-on-year, and tumbling by 21.27% quarter-on-quarter. EBITDA came in at Rs 1823 crore, slipping 5.70% YoY and nosediving by 24.66% sequentially. Total expenses rose by 19.88% to Rs 6642.3 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 1251.2 crore, marginally falling by 7.13% YoY, while employee benefits expense was at Rs 1368.2 crore, rising by 10.45% YoY. For the TTM ended FY26, revenue from operations grew 18.37% to Rs 26719.7 crore, while net profit grew slightly 8.92% to Rs 5026.4 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 728020% to Rs 7965.6 crore, and PBT saw a minor gain of 9.86% to Rs 6621.1 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 2116.6 crore in FY26, as against Rs 6781.1 crore in FY25. Zydus Lifesciences Ltd surged by 17.29% in last one year, significantly outperforming the benchmark BSE Sensex which has eased by 2.56% during the same period.